China SXT Pharmaceuticals
SXTC
2 hedge funds and large institutions have $66K invested in China SXT Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
15% less capital invested
Capital invested by funds: $78K → $66K (-$12K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$87.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $35K | +$87.2K | +2 | New |
|
2
Renaissance Technologies
New York
| $17K | – | – | – |
|
|
HF
3
HRT Financial
New York
| $8K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $6K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| – | -$26K | – | – |
|
SXTC Hedge Fund Activity: Q3 2022 in Review
2 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q3 2022, worth a combined $66K — down 15% from $78K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SXTC positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $87.2K. The largest seller was Virtu Financial, cutting an estimated $26K.
- 2 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q3 2022, up from 1 in Q2 2022.
- Funds reported $66K of China SXT Pharmaceuticals stock for Q3 2022, down 15% quarter-over-quarter.
- 1 fund opened new China SXT Pharmaceuticals positions in Q3 2022 and 0 closed out, a net change of +1 holder.
- The largest China SXT Pharmaceuticals buyer in Q3 2022 was Millennium Management, an estimated $87.2K added.
- The largest China SXT Pharmaceuticals seller in Q3 2022 was Virtu Financial, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2022.